CIFoundry
Back to Catalog
Neurology
FDA Cleared

Cognoa Canvas Dx (Autism Diagnosis Aid)

Save to shortlist
Cognoa, Inc.2021

Last reviewed Oct 31, 2026 against the sources listed on this page · How we review

At a glance

Canvas Dx is an FDA De Novo authorized AI-based diagnostic aid for autism spectrum disorder in children aged 18 to 72 months who are at risk of developmental delay.

FDA:
510(k) K243558 +1 more
Epic:
Not on record
Named users:
Not on record
Published study:
Not on record

Description

Canvas Dx is an FDA De Novo authorized AI-based diagnostic aid for autism spectrum disorder in children aged 18 to 72 months who are at risk of developmental delay. The prescription device combines caregiver questionnaires, caregiver-uploaded home videos analyzed by trained specialists, and a healthcare-provider questionnaire into a machine-learning algorithm that outputs a Positive, Negative or Indeterminate result to support earlier diagnosis by primary-care clinicians. It was the first FDA-authorized autism diagnostic aid of its kind.

neurologyneurodevelopmentalautismpediatricsdiagnostic aidFDA De NovoFDA-cleared

Quick answers

Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review

Is Cognoa Canvas Dx (Autism Diagnosis Aid) FDA cleared?
The public FDA database has 2 records that our team matched to Cognoa Canvas Dx (Autism Diagnosis Aid). The most recent is 510(k) K243558 (Canvas Dx), decided Apr 2025. Check that the cleared use matches how you plan to use it.FDA record K243558

Security & contracting

The maker has not reported these details yet. Ask the vendor directly during evaluation.

Workflow stage
Not reported
Integrations
Not reported
Data inputs
Not reported
Deployment
Not reported
Signs a BAA
Not reported
SOC 2 report
Not reported
HITRUST
Not reported
Evidence type
Not assessed

Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.

Who's using this

Organizations named in public announcements or by the developer. Inclusion is not an endorsement.

No public deployments found yet (checked Oct 2026). Using this tool? The maker can claim the listing to add customers.

Get weekly updates for Neurology

Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.

Sources

This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.

Website

FDA database records

  • K243558 · 510(k) · Apr 2025
    Canvas Dx
  • DEN200069 · De Novo · Jun 2021
    Cognoa ASD Diagnosis Aid

Matched by our team from the public FDA database; checked Nov 10, 2026.

History (3)Show

Dated events on this listing's public record, newest first.

  1. Sep 13, 2026

    Added to CIFoundry

  2. Apr 11, 2025

    FDA 510(k) K243558 decision datesource

  3. Jun 2, 2021

    FDA De Novo DEN200069 decision datesource

https://cognoa.com/contact/ (Palo Alto, CA, USA)

Developer

Cognoa, Inc.

Evaluating this tool?

Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.

Prepare evaluation packet

Checklist for your role: Admin · Physician · IT · Compliance

Compare similar tools →

Own this tool?

Claim this listing to update its details and connect with your audience.